| Product | Licensee(s) | Indications | Preclinical | Phase I | Phase II | Phase III | Market |
|---|---|---|---|---|---|---|---|
| Crysvita® (Status in US only) | Kyowa Kirin Co., Ltd. & Ultragenyx Pharmaceutical Inc. | X-Linked Hypophosphatemia (XLH) Tumor-Induced Osteomalacia (TIO) | Complete | Complete | Complete | Complete | In-progress |
| 16α-hydroxyprogesterone, deoxycorticosterone, 11-deoxycortisol biomarker assay (DocNatal) | Garbha Health, Inc. (dba Nixxi) | Pre-term labor | Complete | Complete | Complete | In-progress | Not Applicable |
| Acamprosate | Confluence Pharmaceuticals | Fragile X Syndrome | Complete | Complete | In-progress | Not Applicable | Not Applicable |
| ABI-H0731 | Assembly Biosciences | Antiviral | Complete | Complete | In-progress | Not Applicable | Not Applicableed |
| APX3330 | Apexian Pharmaceuticals & Ocuphire Pharma | Diabetic Retinopathy/Diabetic Macular Edema | Complete | Complete | In-progress | Not Applicable | Not Applicable |
| Acamprosate | Confluence Pharmaceuticals | Autism Spectrum Disorder | Complete | In-progress | Not Applicable | Not Applicable | Not Applicable |
| APX3330 | Apexian Pharmaceuticals | Cancer | Complete | In-progress | Not Applicable | Not Applicable | Not Applicable |
| Pioglitazone | Not Applicable | Kidney Disease | Complete | In-progress | Not Applicable | Not Applicable | Not Applicable |
| CTI-1601 | Larimar Therapeutics, Inc. | Mitochondrial Disease | Complete | In-progress | Not Applicable | Not Applicable | Not Applicable |
| Optate | Airbase Breathing Company | COVID-19 | Complete | In-progress | Not Applicable | Not Applicable | Not Applicable |
| APX2009 | Apexian Pharmaceuticals, Inc. | Cancer, IBD | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| APX2014 | Apexian Pharmaceuticals, Inc. | Cancer, IBD | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| TRH nanoparticles | MVK Pharmaceuticals (Negotiating) | Anti-suicide/PTSD | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| PRMT5 Inhibitors | EQon Pharmaceuticals, LLC | Cancer and Inflammation | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Human Papilloma Virus (HPV) Antiviral Agents | Kovina Therapeutics, Inc. | Cervical, Anogenital, Oropharyngeal Cancers | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| VSC 100 | Vascugen | Severe ischemic disease | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| EMAP II Mab | Allinaire | Pulmonary Arterial Hypertension | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| NICOTINAMIDE PHOSPHORIBOSYL- TRANSFERASE (NAMPT) INHIBITORS | Drax Therapeutics, Inc.* (Negotiating) | Pulmonary Arterial Hypertension | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Molecular Diagnostics and Drug Development for Mental Health | MindX Sciences Inc. | Suicide, Pain, Stress, Aging | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Soluble Epoxy Hydrolase Inhibitors (SH-11037) | Not Applicable | Ocular Disease | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Ferrochelatase Inhibitors (Griseofulvin) | Not Applicable | Ocular Disease | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| STAT3 Inhibitors | Not Applicable | Cancer | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Survivin Inhibitors | Not Applicable | Cancer | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| GroEL/ES Inhibitors | Not Applicable | Bacterial Infections | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| SHP2 Inhibitors | Not Applicable | Cancer, Autoimmune Disease | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Voltage-gated calcium channel (CaVβ) Inhibitors | Not Applicable | Neuropathic pain | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| TEAD Inhibitors | Not Applicable | Cancer | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| cGMP Related Phosphodiesterases inhibitors | Not Applicable | Polcystic kidney disease | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| HOTAIR/PRC2 interaction inhibitors (peptide-nucleic acid based) | Not Applicable | Ovarian cancer | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| nNOS-PSD95 disruptor | Not Applicable | Opioid addiction | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| GPR119 Antagonist | Not Applicable | Dry eye | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Poly(ADP-ribose) polymerase inhibitors (PARPi) | Not Applicable | Cancer | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| VEGF Receptor Inhibitor | Not Applicable | Cancer | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| Novel COVID-19 Vaccine | Not Applicable | Coronavirus | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
| TRVP4 antagonists | Not Applicable | Hydrocephalus | In-progress | Not Applicable | Not Applicable | Not Applicable | Not Applicable |
